New treatment modalities with vaccine therapy in renal cell carcinoma

Basit Öğe Kaydı
dc.contributor.authorSonmez, Mehmet Giray
dc.contributor.authorSonmez, Leyla Ozturk
dc.date.accessioned2024-02-23T14:37:57Z
dc.date.available2024-02-23T14:37:57Z
dc.date.issued2019
dc.departmentNEÜen_US
dc.description.abstractThe aim of implementing vaccine therapy is to activate immune response against malignant cells by overcoming the tolerance triggered by the tumor. These treatments are effective using the immune response against cancer. Not every type of cancer is suitable for vaccine therapies. For a vaccine therapy to be implemented, cancer should be immunogenic and contain tissue-specific proteins, should have a slow progression, and treatments should be feasible. For that reason, studies regarding urological cancers are mostly focused on the kidneys and the prostate. Vaccine therapies used in renal cell carcinoma (RCC) can be categorized under the following titles: autologous tumor cells, dendritic cells, genetically modified tumor cells, and protein/peptide. Although there are old studies on the implementation of vaccine therapies in RCC, researches have only been intensified recently. In addition to their effective potential for lengthening general survival, decreasing tumor burden and cancer development in long term, vaccine treatments are especially effective in metastatic RCC patients. We think that vaccine treatments would be applied more in near future since RCC are immunogenic. In this compilation, we will discuss vaccine therapies used in RCC, which urologists are not so familiar with, in the light of the up-to-date literature.en_US
dc.identifier.doi10.4103/UA.UA_166_17
dc.identifier.endpage125en_US
dc.identifier.issn0974-7796
dc.identifier.issn0974-7834
dc.identifier.issue2en_US
dc.identifier.pmid31040593en_US
dc.identifier.scopus2-s2.0-85063944234en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage119en_US
dc.identifier.urihttps://doi.org/10.4103/UA.UA_166_17
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16301
dc.identifier.volume11en_US
dc.identifier.wosWOS:000463521900001en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofUrology Annalsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAutologous Tumor Cellen_US
dc.subjectDendritic Cellen_US
dc.subjectImmunotherapyen_US
dc.subjectRenal Cell Carcinomaen_US
dc.subjectVaccine Therapyen_US
dc.titleNew treatment modalities with vaccine therapy in renal cell carcinomaen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu